6/22/2018 1 Asthma Update NEETA THAKUR MD, MPH ZUCKERBERG SAN FRANCISCO GENERAL UNIVERSITY OF CALIFORNIA, SAN FRANCISCO MAY 11, 2018 Disclosure(s) Spouse employed by Roche/Genentech Learning Objectives •To review updates in Asthma • Screening • Categorizing • Treatment • Non-pharmacologic therapies • Managing severe asthma and when to refer •A paradigm switch: What are asthma phenotypes? What is asthma? - Tightening of Airways - Airway Remodeling - Thick Mucus Production - Acute and Chronic Phases - Wheezing - Coughing - Shortness of Breath
17
Embed
33 Thakur Asthma - UCSF CME · 2018. 6. 26. · ò l î î l î ì í ô î t Z ] Z u M Z u v ( ( ] À o Ç ô ì 9 u v P ] v ] u Ç t Z v Z u ] Á o o r } v } o o U ] v v
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
6/22/2018
1
Asthma UpdateNEETA THAKUR MD, MPH ZUC KERBERG SAN FR ANCI SCO G ENERAL
UNIV ERSITY OF CAL IFOR NIA, SAN FR ANC ISCO
M AY 11, 2 018
Disclosure(s)Spouse employed by Roche/Genentech
Learning Objectives•To review updates in Asthma
• Screening• Categorizing • Treatment
• Non-pharmacologic therapies• Managing severe asthma and when to refer
•A paradigm switch: What are asthma phenotypes?
What is asthma?- Tightening of Airways- Airway Remodeling- Thick Mucus Production- Acute and Chronic Phases
- Wheezing- Coughing- Shortness of Breath
6/22/2018
2
What is asthma? Asthma can be effectively treated~ 80% managed in primary care
When asthma is well-controlled, patients can• Avoid troublesome symptoms• Need little or no reliever medication• Have productive, physically active lives• Have normal or near-normal lung function• Avoid serious asthma exacerbations
Does NOT equal symptom-free
Diagnosis
The diagnosis of asthma should be based on:◦ Characteristic symptom patterns ◦ Evidence of variable airflow limitation
◦ bronchodilator reversibility testing
Document evidence for the diagnosis◦ Preferably before starting controller treatment◦ Difficult to confirm diagnosis after treatment has been started
Why? When combined with self-monitoring and regular medical review, action plans are highly effective in reducing asthma mortality and morbidity
All patients should have a written asthma action plan
◦ Recognize and Respond◦ Individualized: medications, level of
asthma control and health literacy◦ Based on symptoms and/or PEF
The action plan should include: ◦ Usual asthma medications◦ When/how to increase reliever and
controller or start OCS◦ How to access medical care if
symptoms fail to respond
Pharmacological Interventions
Choosing between controller options Decisions for individual patientsUse shared decision-making with the patient/parent/carer to discuss the following:
1. Preferred treatment for symptom control and for risk reduction2. Patient characteristics (phenotype)
• Does the patient have any known predictors of risk or response? (e.g. smoker, history of exacerbations, blood eosinophilia)
3. Patient preference• What are the patient’s goals and concerns for their asthma?
4. Practical issues• Inhaler technique - can the patient use the device correctly after training?• Adherence: how often is the patient likely to take the medication?• Cost: can the patient afford the medication?
GINA 2017, Box 3-3 (2/2)
6/22/2018
8
Step-wise Management
STEP 1
PREFERRED CONTROLLER
CHOICE
Other controller
options
RELIEVER As-needed short-acting beta2-agonist (SABA)As-needed SABA or low dose ICS/formoterol
Consider low dose ICS
Low dose ICS
STEP 2
STEP 3
STEP 4
STEP 5
Low dose ICS/LABA
Leukotriene receptor antagonists (LTRA),
Low dose theophylline
Med/high dose ICS,Low dose ICS+LTRA
(or + theophylline)
Med/high ICS/LABA
Add tiotropium, High dose ICS + LTRA (or + theophylline)
Refer for add-on
treatment e.g.
tiotropium, anti-IgE, anti-IL5
Add low dose OCS
Where to start? Based on symptoms & severityWhen to go UP or DOWN? Based on control
Step-wise Management
STEP 1
PREFERRED CONTROLLER
CHOICE
Other controller
options
RELIEVER As-needed short-acting beta2-agonist (SABA)As-needed SABA or low dose ICS/formoterol
Consider low dose ICS
Low dose ICS
STEP 2
STEP 3
STEP 4
STEP 5
Low dose ICS/LABA
Leukotriene receptor antagonists (LTRA),
Low dose theophylline
Med/high dose ICS,Low dose ICS+LTRA
(or + theophylline)
Med/high ICS/LABA
Add tiotropium, High dose ICS + LTRA (or + theophylline)
Refer for add-on
treatment e.g. SLIT,
tiotropium, anti-IgE, anti-IL5
Add low dose OCS
How often should asthma be reviewed?Reassess every:• 1-3 months after treatment started, then every 3-12 months• After an exacerbation, within 1 week
Stepping up asthma treatment◦ Sustained step-up, for at least 2-3 months if asthma poorly controlled◦ Short-term step-up, for 1-2 weeks, e.g. with viral infection or allergen
Stepping down asthma treatment◦ Consider step-down after good control maintained for 3 months◦ Find each patient’s minimum effective dose, that controls both symptoms and
exacerbations
Step UP or Step DOWNConsider stepping up if …
- Uncontrolled symptoms
- Exacerbations or risks
**First Check- Is this the right diagnosis?
- Inhaler technique
- Adherence first
Consider stepping down if …
- Symptoms controlled for 3 months - Low risk for exacerbations
*** Ceasing ICS is not advised.
SustainedVs.
Short-Term?25%
6/22/2018
9
Patients at increased risk of asthma-related death should be identified◦ Any history of near-fatal asthma requiring intubation and ventilation◦ Hospitalization or emergency care in last 12 months◦ Not currently using ICS, or poor adherence with ICS◦ Recent oral steroid use◦ Over-use of SABAs (more than 1 canister/month)◦ NO written asthma action plan◦ Psychiatric disease or psychosocial problems◦ Confirmed food allergy
Flag these patients for more frequent review
Identify patients at risk of asthma-related death
GINA 2017, Box 4-1
Identifying Severe/Refractory asthmaContinuous or near-continuous oral steroidsHigh-dose ICS
Additional daily controllerUse of SABA on a near-daily basisPersistent airway obstructionFEV1 < 80%Diurnal variation in PF ≥ 25%≥ 1 urgent care visit per year≥3 or more steroid bursts per yearPrompt deterioration with 25% reduction in steroid doseEpisode of near-fatal asthma
Minor(2)
Major(≥1)
ATS AJRCCM 2000; 162:2341-51
Asthma is a complex diseasePhenotypes
WENZEL NATURE MEDICINE VOLUME 18, PAGES 716–725 (2012)
Asthma Phenotypes
6/22/2018
10
Non-eosinophilicCh
ildho
od
Adul
t
Eosinophilic
Asthma Phenotypes
Dust mites Pollens
EosinophilsElevated in bronchial bx, induced sputum, or peripheral bloodCorticosteroid naïve patients: ≥2.7% (blood)Who has high Eos?o“Childhood-onset” and allergy to airborne allergens
Who does Not?o“Late-onset” non-atopic disease
Associated with?oPersistence on high-dose ICS or PO steroids associated with
symptomatic and exacerbation-prone disease
Non-eosinophilic
Child
hood
Adul
t
Eosinophilic
Asthma Phenotypes
Allergic Intrinsic
Dust mites Pollens
How do you identify this group?Total IgE
Sum of total IgESometimes reported as %total IgG (0.05% normal)60% of allergic asthma (includes HMW OA)Poor PPV and NPV compared to allergen-specific IgE
6/22/2018
11
Dust mites Pollens
How do you identify this group? Skin prick allergy testingFalse negatives:–OTC antihistamines (48 hours)–Allegra, Clarinex, Zyrtec and Astelin (Azelastin) nasal spray (5 days)–PO steroids (25 mg prednisone) (3 weeks)–High dose topical steroids (3 weeks)
Dust mites Pollens
How do you identify this group? Radioallergosorbant IgE (RAST)Allergen-specific IgELess sensitive and specific than skin testingRational starting point:–Specific HMW candidate antigen(s) (some LMW antigens)–Determine positive aeroallergen–Grasses, weeds, dust mites, molds–Low predictive value for food allergies
What do these have in common? When to do obstruction testing for Occupational Asthma?Preferably performed toward the end of a typical work week and within 24 hr of the occurrence of symptoms
Active panel patients with DMNon-eosinophilic
Occupational (non-sensitized)
Asthma Phenotypes
Child
hood
Allergic IntrinsicAdult
Eosinophilic
Occupational (sensitized)
What’s the Asthma Phenotype?
34 year old man
Persistent rhinitis at age 30, watery rhinorrhea
Cough, wheeze
Sudden acute event requiring ED visit
No previous history of asthma
6/22/2018
13
B. Ghorayeb, MD
Asthma-Exacerbated Asthma
6/22/2018
14
Aspirin-Exacerbated Asthma: diagnosisReferral to Specialist
•Exacerbation after ingestion of aspirin or other non-NSAIDs
•Starts with intractable nasal congestion and watery rhinorrhea
•Refractory to pharmacologic treatment (benefit with leukotriene inhibitors)
•Specific IgE tests negative
•Treatment may include desensitization to aspirin
Active panel patients with DMNon-eosinophilic
Child
hood Adult
EosinophilicAspirin
Cough variant
Air pollution
Asthma Phenotypes
Allergic Intrinsic
Occupational (sensitized)
Occupational (non-sensitized)
EIACigarette
Leiria, 2014
Obese Asthma Phenotype
6/22/2018
15
Active panel patients with DMNon-eosinophilic
Child
hood Adult
EosinophilicAspirin
Cough variant
Air pollution
Asthma Phenotypes
Allergic Intrinsic
Occupational (sensitized)
Occupational (non-sensitized)
EIACigarette
Infection-related
Obesity
Active panel patients with DMNon-eosinophilic
Child
hood Adult
EosinophilicAspirin
Cough variant
Air pollution
Asthma Phenotypes
Allergic Intrinsic
Occupational (sensitized)
Occupational (non-sensitized)
EIACigarette
Infection-related
Obesity
Exacerbation-prone
Treatment Options Based on Phenotypes
TARGETED AT Th2 (ALLERGIC) ASTHMA
Treatments based on Phenotypes -OmalizumabBest Candidates:
High IgE
Known Allergen
BMI
6/22/2018
16
Hanania Ann Intern Med 2011, Busse NEJM 2011
Treatments based on Phenotypes - Omalizumab
Asthma Exacerbations
25% reduction
IL-5: Key cytokine in eosinophil oDifferentiationoRecruitmentoActivationoSurvival
Best Candidates:o- High Eosinophilso- 2 or greater exacerbations/yro- On high dose ICS
Fulkerson Nature Review Drug Discovery 2013
Treatments based on Phenotypes – Anti-IL5/IL5R
MENSA trial (RCT), selected for high eosinophils, mod-high dose ICS
Treatments based on Phenotypes -Mepolizumab
Asthma Exacerbations and FEV1 at 32 Weeks.
Ortega NEJM 2014 (Sponsored by Glaxo-Smith Kline)
50% reduction
Side Effects and Adverse ReactionsOmalizumab
Anaphylaxis (must have epi-pen)◦ 0.1-0.2% ◦ Can occur as late as 1 year
? Malignancy (0.5 vs. 0.2% in RCT)◦ Longer observation trials underway
Pain and arthralgia
Injection site bruising/pain
Mepolizumab/Anti-IL5 Therapy
No observed risk of anaphylaxis
Muscle pain
Fatigue
Injection site bruising/pain
6/22/2018
17
In SummaryASTHMA IS COMPLEX!!!
But majority can be controlled in primary care
Look at multiple data points, including◦ Age◦ Patient specific data: BMI, occupation ◦ Triggers◦ Disease course◦ Biomarkers